Group One Trading
SPRY icon

Group One Trading’s ARS Pharmaceuticals SPRY Stock Holding History

Group One Trading’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.6K Buy
+200
New +$1.72K ﹤0.01% 7083
2025
Q4 		– Sell
-3,200
Closed -$32.2K – 9102
2025
Q3 		$32.2K Sell
3,200
-22,300
-87% -$320K ﹤0.01% 6309
2025
Q2 		$445K Sell
25,500
-2,400
-9% -$34.6K ﹤0.01% 3537
2025
Q1 		$351K Buy
27,900
+24,700
+772% +$297K ﹤0.01% 3440
2024
Q4 		$33.8K Sell
3,200
-5,800
-64% -$81.2K ﹤0.01% 5356
2024
Q3 		$131K Buy
9,000
+6,000
+200% +$71.4K ﹤0.01% 3966
2024
Q2 		$25.5K Sell
3,000
-50,000
-94% -$444K ﹤0.01% 5050
2024
Q1 		$542K Sell
53,000
-127,100
-71% -$948K ﹤0.01% 2652
2023
Q4 		$987K Sell
180,100
-91,200
-34% -$400K ﹤0.01% 2471
2023
Q3 		$1.03M Buy
271,300
+238,900
+737% +$1.57M ﹤0.01% 2245
2023
Q2 		$217K Buy
32,400
+19,100
+144% +$127K ﹤0.01% 3838
2023
Q1 		$86.6K Buy
+13,300
New +$102K ﹤0.01% 4420
2022
Q4 		– Sell
-49,200
Closed -$260K – 8037
2022
Q3 		$260K Buy
49,200
+17,400
+55% +$85.7K ﹤0.01% 3895
2022
Q2 		$135K Buy
+31,800
New +$111K ﹤0.01% 4692

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Group One Trading's SPRY Position: Q2 2026 in Review

Group One Trading reduced its ARS Pharmaceuticals (SPRY) stake by 99% in Q2 2026, selling an estimated $101K and leaving 125 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #7182.

Group One Trading first reported a position in SPRY in Q1 2022 and has held it in 9 quarters since. The position peaked at $732K in Q3 2024. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Group One Trading held 125 shares of ARS Pharmaceuticals worth $1K as of Q2 2026.
  • Group One Trading sold 11,762 ARS Pharmaceuticals shares in Q2 2026, an estimated $101K.
  • ARS Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #7182 holding.
  • Group One Trading first reported a position in ARS Pharmaceuticals in Q1 2022 and has held it in 9 quarters since.
  • Group One Trading's ARS Pharmaceuticals position peaked at $732K in Q3 2024.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.